patent analysis in this report are remdesivir, ruxolitinib, favipiravir, molnupiravir and nirmatrelvir, and the … biotherapeutics tocilizumab, siltuximab and sarilumab. … support national patent offices and interested parties in developing countries with information that can serve as guidance for …

prevention of COVID-19. The aim of the report is to support national patent offices and interested parties in developing … countries with information that can serve as guidance for the examination of the claims contained in relevant patents or patent … applications. The antibody combination considered for the patent analysis in this paper are Casirivimab and Imdevimab. The vaccines …